platoseedplatoseed
Enabling next generation medicines. A comprehensive platform and…
The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up. Our VectorSelect platform is designed to unlock the scale these therapies need to survive. We combine massively parallelized screens with computational insights to engineer high yield cell lines and production technologies — accelerating the manufacturing of advanced therapies from the inside out.
64x Bio provides a platform and product suite aimed at enabling scalable manufacturing for next-generation medicines, focusing on engineering high-yield production cell lines and manufacturing technologies. It combines parallelized screening with computational insights to optimize production for AAV, lentivirus, and biologics through its VectorSelect platform and AAV Apex Suite.
64x Bio offers VectorSelect to optimize production cell lines using massively parallelized screens and computational insights, accelerating manufacturing of advanced therapies. The AAV Apex Suite delivers high-yield cell lines and production technologies for AAV at scale, independently validated across serotypes, payloads, and scales. It also provides VectorSelect-based optimization for lentivirus production and a broad biologics optimization workflow, enabling scalable, improved manufacturing from the inside out.
Who it’s for: Biotech companies and contract development/manufacturing organizations (CDMOs) focusing on gene therapy, cell therapy, and biologics manufacturing requiring scalable production cell lines and high-yield production technologies.
News mentions and product launches (e.g., 2025 news release), licensing partnerships
Lexi Rovner, PhD is the CEO & co-founder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute. Lexi completed her PhD at Yale University and her postdoctoral work in George Church’s lab at Harvard Medical School, where she co-founded the company alongside George, Pam Silver, Jeff Way, and David Thompson. Lexi is a Y Combinator alum, a 2022 Endpoints 20 under 40 Next-Generation Biotech Leader, and a 2022 Bloomberg New Economy Catalyst Awardee.
Formerly “64-X” · why startups rename →
We grow cells for biotech companies.
Delivering RNA therapies.
